Forward Look New Therapies for Metastatic Lung Cancer Several targeted drugs were approved in 2020 to treat the most common type of lung cancer. by Ashley P. Taylor When Cancer’s Spread Is Limited People with cancer that has spread to only a few locations—called oligometastatic cancer—may benefit from aggressive local treatment. by Kate Yandell Survivor Profile A Return to Carnival With a renewed sense of purpose, stage IV lung cancer survivor Oswald Peterson returns to his parents’ native Trinidad to celebrate the Caribbean festival. by Lindsey Konkel Immunotherapy Indications Withdrawn In recent months, drugmakers have announced they are withdrawing indications for four immune checkpoint inhibitors in consultation with the Food and Drug Administration. What does this mean for patients who are taking these drugs? by Anna Goshua Forward Look Scanning Disparities Whether lung cancer patients receive PET scans depends on race, according to a study. by Ashley P. Taylor Forward Look Support Services Help Improve Patient Outcomes Study suggests far-reaching benefits of mental health treatment. by Sharon Tregaskis More Choices to Treat Lung Cancer Advances in precision medicine and immunotherapy have led to better treatments for many patients with advanced lung cancer. But having a wider selection of therapies to choose from can make treatments more complex. by Kendall K. Morgan Targeted Therapy for Early-Stage Lung Cancer? A trial of the targeted therapy Tagrisso (osimertinib) for early-stage lung cancer finds that patients who take it go longer without having a cancer recurrence. Whether that should change clinical practice is under discussion. by Ashley P. Taylor Forward Look Cancer Death Rate Decline Makes Headlines Experts say it’s necessary to look behind the statistics. by Delia O’Hara Caregiving With Confidence The Power of Anger Accepting this emotion can be the first step in channeling it for a constructive purpose. by Karen J. Bannan next Cancer Talk Remote Care After adapting remote patient monitoring programs to cancer patients with COVID-19, cancer centers delve deeper into the programs’ value for cancer patients undergoing treatment. by Jon Kelvey Moving Away From the Maximum Tolerated Dose The FDA recently expressed a new commitment to testing cancer drugs at lower doses, rather than defaulting to the highest dose most people can tolerate. by Marcus A. Banks The Individual Sphere of Influence Can discussion of health inequities lead to actionable change? by Marci A. Landsmann A Treatment That Came Just in Time Cancer survivor Laurie Adami reflects on her experience participating in a clinical trial that ultimately contributed to the March 2021 approval of a CAR-T cell therapy for follicular lymphoma. by Laurie Adami More Posts